Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Aug 5, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
- Aug 5, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Aug 4, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record1,80015 flagged findings
Reported transactions (Form 4)80since Jun 12, 2024 · and 8 other holdings
Corporate events (8-K)30since Nov 22, 2021
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-06capital return (buybacks/dividends)recentOpen filing ↗“…regulatory or clinical results, including post-approval clinical commitments, a change in business strategy, a change of control or…”
- 2026-05-06regulatory investigationrecentOpen filing ↗“…authorities, competitors, and other third parties may take the position that we are not in compliance with such regulations.…”
- 2026-05-06Department of Justice inquiryrecentOpen filing ↗“…and regulations, we could face substantial penalties. Our and our partners’ activities related to approved products or, following…”
- 2026-05-06merger or acquisition eventrecentOpen filing ↗“…a material impact to its condensed consolidated financial statements or disclosures. Note 2 — Acquisition of Astria Therapeutics,…”
+1 more passage from the same document
- “…the treatment of Netherton syndrome, which will enroll up to 12 patients for three months. Avoralstat In the first quarter of 2026,…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 1,800)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Aug 14, 26SCHEDULE 13G/A ↗Passive stake · RA Capital Management, L.P. · 6.2% · event on Jun 30, 26 · amendment
- Aug 7, 26SCHEDULE 13G ↗Passive stake · STATE STREET CORPORATION · 6.0% · event on Jun 30, 26
- Aug 5, 2610-Q ↗Quarterly report
- Aug 5, 268-K ↗Current report · Results · Communication to the market
- Aug 4, 268-K/A ↗Current report · Restructuring plan with committed costs · amendment
- Jun 29, 268-K ↗Current report · Restructuring plan with committed costs
Insider transaction · 9 Form 4 filingsshow all 9hide
- Jun 15, 26Form 4 ↗Insider transaction
- Jun 15, 26Form 4 ↗Insider transaction
- Jun 15, 26Form 4 ↗Insider transaction
- Jun 15, 26Form 4 ↗Insider transaction
- Jun 15, 26Form 4 ↗Insider transaction
- Jun 15, 26Form 4 ↗Insider transaction
- Jun 15, 26Form 4 ↗Insider transaction
- Jun 15, 26Form 4 ↗Insider transaction
- Jun 15, 26Form 4 ↗Insider transaction
- Jun 12, 268-K ↗Current report · A senior executive left or was appointed
1,800 filings on record, the oldest from Feb 14, 95.
Listing the 25 most recent filings of the 1,800 on record.
37286
- Aug 4, 26Restructuring plan with committed costs8-K/A 2.05 ↗
- Jun 29, 26Restructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
- Jun 12, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jan 23, 26A senior executive left or was appointed8-K/A 5.02 ↗
- Jan 23, 26Took on a new financial obligation+4 more in the same filing8-K 2.03 ↗
- Dec 11, 25A senior executive left or was appointed8-K 5.02 ↗
- Oct 14, 25Entered a material agreement+4 more in the same filing8-K 1.01 ↗
- Oct 1, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
3 senior executive changes2025show all 3hide
- Aug 11, 25A senior executive left or was appointed8-K 5.02 ↗
- Jul 31, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jul 7, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jun 30, 25Entered a material agreement+1 more in the same filing8-K 1.01 ↗
9 senior executive changes2023 – 2025show all 9hide
- Jun 16, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jun 4, 25A senior executive left or was appointed8-K 5.02 ↗
- May 1, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Apr 10, 25A senior executive left or was appointed8-K 5.02 ↗
- Mar 4, 25A senior executive left or was appointed8-K 5.02 ↗
- Jun 13, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Dec 1, 23A senior executive left or was appointed8-K 5.02 ↗
- Jul 11, 23A senior executive left or was appointed8-K 5.02 ↗
- Jun 14, 23A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Apr 18, 23Took on a new financial obligation+3 more in the same filing8-K 2.03 ↗
4 older filings not shown · The record reaches back to Feb 7, 05.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Dec 7, 12Restructuring plan with committed costs+3 more in the same filing8-K 2.05 ↗
The full record holds 3 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- BlackRock, Inc.8.4%Mar 31, 25SCHEDULE 13G/A ↗
- Deerfield Mgmt, L.P.6.8%Dec 31, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- RA Capital Management, L.P.6.2%Jun 30, 26SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- STATE STREET CORPORATION6.0%Jun 30, 26SCHEDULE 13G ↗2 earlier filings
- Vanguard Capital Management5.2%Mar 31, 26SCHEDULE 13G ↗
show one more holderhide
- Avoro Capital Advisors LLC4.2%Mar 31, 25SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Stock compensation, tax and giftsshow the 35 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Aug 31, 26Compensation$12KSteven Frank↗
- Aug 31, 26Compensation$6KAmy E McKee↗
- Aug 31, 26Compensation$11KVINCENT MILANO↗
- Aug 31, 26Compensation$12KJill C. Milne↗
- Aug 31, 26Compensation$6KJon P Stonehouse↗
- Jun 11, 26Compensationamount n/aTHERESA HEGGIE↗
- Jun 11, 26Compensationamount n/aAmy E McKee↗
- Jun 11, 26Compensationamount n/aJon P Stonehouse↗
- Jun 11, 26Compensationamount n/aVINCENT MILANO↗
- Jun 11, 26Compensationamount n/aMACHELLE SANDERS↗
- Jun 11, 26Compensationamount n/aSteven Frank↗
- Jun 11, 26Compensationamount n/aALAN G LEVIN↗
- Jun 11, 26Compensationamount n/aSteven K Galson↗
- Jun 11, 26Compensationamount n/aJill C. Milne↗
- May 29, 26Compensation$11KSteven Frank↗
- May 29, 26Compensation$10KVINCENT MILANO↗
- May 29, 26Compensation$6KAmy E McKee↗
- May 29, 26Compensation$6KJon P Stonehouse↗
- May 29, 26Compensation$11KJill C. Milne↗
- May 13, 26Compensation$315KAlane P BarnesChief Legal Officer↗
- Apr 6, 26Compensationamount n/aSandeep MenonChief R&D Officer↗
- Mar 20, 26Compensation$315KTHERESA HEGGIE↗
- Mar 16, 26Compensation$827KAlane P BarnesChief Legal Officer↗
- Mar 2, 26Compensation$985KJon P Stonehouse↗
- Mar 2, 26Other$2.6MJon P Stonehouse↗
- Feb 27, 26Compensation$6KAmy E McKee↗
- Feb 27, 26Compensation$11KSteven Frank↗
- Feb 27, 26Compensation$7KVINCENT MILANO↗
- Feb 27, 26Compensation$4KJon P Stonehouse↗
- Feb 27, 26Compensation$5KJill C. Milne↗
- Jan 23, 26Compensationamount n/aJill C. Milne↗
- Jan 23, 26Compensationamount n/aJill C. Milne↗
- Dec 22, 25Compensation$46KCharles K GayerPresident and CCO↗
- Dec 22, 25Compensation$51KCharles K GayerPresident and CCO↗
- Dec 22, 25Compensation$276KCharles K GayerPresident and CCO↗
The full record holds 175 transactions and goes back to Dec 29, 22.
Its sector and its market
BioCryst Pharmaceuticals Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From BioCryst Pharmaceuticals Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow BioCryst Pharmaceuticals Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 1,800 documents on file, from Feb 14, 1995 to Sep 2, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.